Clinical Data and George Washington University to Examine the Impact of Genetic Testing in Warfarin Treatment
News Jul 25, 2007
The PGxHealth division of Clinical Data, Inc. and The George Washington University Medical Faculty Associates Department of Orthopaedic Surgery announced that they have established a relationship to examine the integration of genomic testing in warfarin treatment.
The program will be implemented in an orthopaedic practice setting during a patient's normal course of treatment, enrolling 80 patients who have been prescribed the blood thinner warfarin as a treatment measure following orthopaedic surgery.
Of those 80 patients, a randomly-assigned half will have their warfarin dose determined with the help of PGxPredict™:WARFARIN in order to evaluate the potential clinical, safety and treatment-time benefits of using the genetic test to determine optimal warfarin dosing.
The program has already received approval from the University Institutional Review Board and is open to enrollment. If the program results are positive, pharmacogenetic testing could be incorporated into the Clinic's routine practice.
"Warfarin is a drug with both valuable benefits and serious risks, so it is an ideal candidate for assessing whether pharmacogenetic testing can improve patient outcomes and reduce treatment costs," said Dr. Carol Reed, Clinical Data's Chief Medical Officer.
"Clinical Data and the GW Medical Faculty Associates hope to assess the value of tests such as PGxPredict™ WARFARIN in a typical practice setting. Combined with its proprietary genetic tests for clozapine safety and rituximab efficacy, Clinical Data seeks to transform advances in molecular biology into clinical products to benefit patients, physicians and payers," Dr. Reed continued.
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018